News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Apthera, Inc. Announces Optimal Dose And Schedule Of Neuvax For Phase III Clinical Trial In Breast Cancer


10/1/2008 10:01:45 AM

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Apthera, Inc. announced the optimized dose and schedule for its lead drug, NeuVax, in treating early-stage breast cancer patients to be used in Phase III clinical trials. Dr. George Peoples, Deputy Director, United States Military Cancer Center, co-authored a publication that appears on the cover of the October 1, 2008, issue of Cancer (Vol.113 Issue 7:1666-75) and details the Phase I/II clinical study results.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES